^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

WNT974

i
Company:
Novartis
Drug class:
Wnt signalling pathway inhibitor, PORCN inhibitor
Phase 1
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
05/30/2024
Initiation :
12/01/2011
Primary completion :
06/14/2021
Completion :
06/18/2024
BRAF • RNF43
|
BRAF mutation • RNF43 mutation
|
spartalizumab (PDR001) • WNT974
Phase 1/2
Array BioPharma
Completed
Last update posted :
10/09/2017
Initiation :
12/01/2014
Primary completion :
05/31/2016
Completion :
06/23/2017
KRAS • RNF43
|
KRAS mutation • BRAF V600 • KRAS wild-type • RAS wild-type • RNF43 mutation
|
Erbitux (cetuximab) • Braftovi (encorafenib) • WNT974